XML 87 R4.htm IDEA: XBRL DOCUMENT v3.24.0.1
Condensed Consolidated Statement of Stockholders' Equity (Unaudited) - USD ($)
$ in Thousands
Total
Common Stock
Additional Paid-in Capital
Treasury Stock
Retained Earnings
Accumulated Other Comprehensive Loss
Beginning balance at Apr. 30, 2022 $ 35,694 $ 6,983 $ 4,483 $ (53) $ 28,023 $ (3,742)
Increase (Decrease) in Stockholders' Equity [Roll Forward]            
Net earnings (loss) attributable to Kewaunee Scientific Corporation (747)       (747)  
Other comprehensive loss (224)         (224)
Stock-based compensation (37) 97 (134)      
Ending balance at Jul. 31, 2022 34,686 7,080 4,349 (53) 27,276 (3,966)
Beginning balance at Apr. 30, 2022 35,694 6,983 4,483 (53) 28,023 (3,742)
Increase (Decrease) in Stockholders' Equity [Roll Forward]            
Net earnings (loss) attributable to Kewaunee Scientific Corporation (267)          
Other comprehensive loss (567)          
Ending balance at Jan. 31, 2023 35,351 7,084 4,873 (53) 27,756 (4,309)
Beginning balance at Jul. 31, 2022 34,686 7,080 4,349 (53) 27,276 (3,966)
Increase (Decrease) in Stockholders' Equity [Roll Forward]            
Net earnings (loss) attributable to Kewaunee Scientific Corporation (243)       (243)  
Other comprehensive loss (237)         (237)
Stock-based compensation 196 4 192      
Ending balance at Oct. 31, 2022 34,402 7,084 4,541 (53) 27,033 (4,203)
Increase (Decrease) in Stockholders' Equity [Roll Forward]            
Net earnings (loss) attributable to Kewaunee Scientific Corporation 723       723  
Other comprehensive loss (106)         (106)
Stock-based compensation 332 0 332      
Ending balance at Jan. 31, 2023 35,351 7,084 4,873 (53) 27,756 (4,309)
Beginning balance at Apr. 30, 2023 37,409 7,084 5,059 (53) 28,761 (3,442)
Increase (Decrease) in Stockholders' Equity [Roll Forward]            
Net earnings (loss) attributable to Kewaunee Scientific Corporation 2,474       2,474  
Other comprehensive loss (144)         (144)
Stock-based compensation (309) 185 (494)      
Ending balance at Jul. 31, 2023 39,430 7,269 4,565 (53) 31,235 (3,586)
Beginning balance at Apr. 30, 2023 37,409 7,084 5,059 (53) 28,761 (3,442)
Increase (Decrease) in Stockholders' Equity [Roll Forward]            
Net earnings (loss) attributable to Kewaunee Scientific Corporation 7,727          
Other comprehensive loss (435)          
Ending balance at Jan. 31, 2024 $ 44,083 7,270 5,046 (844) 36,488 (3,877)
Increase (Decrease) in Stockholders' Equity [Roll Forward]            
Purchase of treasury stock (in shares) 29,456          
Beginning balance at Jul. 31, 2023 $ 39,430 7,269 4,565 (53) 31,235 (3,586)
Increase (Decrease) in Stockholders' Equity [Roll Forward]            
Net earnings (loss) attributable to Kewaunee Scientific Corporation 2,732       2,732  
Other comprehensive loss (251)         (251)
Stock-based compensation 241 0 241      
Purchase of Treasury Stock, 2,423 shares (44)     (44)    
Ending balance at Oct. 31, 2023 $ 42,108 7,269 4,806 (97) 33,967 (3,837)
Increase (Decrease) in Stockholders' Equity [Roll Forward]            
Purchase of treasury stock (in shares) 2,423          
Net earnings (loss) attributable to Kewaunee Scientific Corporation $ 2,521       2,521  
Other comprehensive loss (40)         (40)
Stock-based compensation 241 1 240      
Purchase of Treasury Stock, 2,423 shares (747)     (747)    
Ending balance at Jan. 31, 2024 $ 44,083 $ 7,270 $ 5,046 $ (844) $ 36,488 $ (3,877)
Increase (Decrease) in Stockholders' Equity [Roll Forward]            
Purchase of treasury stock (in shares) 27,033